PharmiWeb

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

VANCOUVER, BC / ACCESS Newswire / May 8, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that Nucro-Technics Inc.
PharmiWebOpinion

EU Regulators Say Charlotte's Web Hemp CBD Safety "Cannot Be Established" - So Why Is It Entering Medicare?

"As a Federal Lawsuit Challenges the CMS Cannabinoid Program, Questions Mount Over Safety Standards, Scientific Validation, ...
PharmiWeb

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026

HILLSIDE, NJ / ACCESS Newswire / May 8, 2026 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2026.Revenue for the ...
PharmiWeb

Bruno Vision Care Wins 2026 MedTech Breakthrough Award

Landmark 10th Annual Awards Program Recognizes the Deseyne® Extended Depth of Focus (EDOF) contact lens as the “Best New ...
PharmiWeb

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in ...
PharmiWeb

Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease E…

Actio launches dedicated patient resource to support families seeking information about the KYRON clinical trial at ...
PharmiWeb

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 reportEPS outlook upgraded: Zacks now expects Cosmos Health to cross into positive EPS ...
PharmiWeb

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's ...

SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock ...
PharmiWeb

Life Science Consulting Services Market Analysis, Size, Share, Trends, Demand, Overview and Segment Forecast To 2029

Growing adoption of digital technologies in life science; expansion of real-world evidence data and its adoption by ...
PharmiWeb

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage ...
PharmiWeb

Assertio and Garda Mutually Agree to Delay Launch of Tender Offer

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to delay the launch of the ...
PharmiWeb

Black Book Nurses Week Survey: Payer Delays Are Reaching the Bedside Before Hospital C-Suite Sees the Damage

Third report in Black Book's five-month Nurses Week research series warns that prior authorization, denials, formulary barriers, and opaque payer decisions are creating hidden nursing workload, ...